Global life sciences company, Cytiva, is creating solutions to the challenges of viral vector-based gene therapies with its new ELEVECTA cell lines.   According to Emmanuel Abate, President Genomic Medicine, Cytiva: “To make gene therapy a realistic option for more patients, we need to be able to standardize its manufacturing. We’ve gone to the heart of the process by creating viral vector cell lines that will make a big impact to developers of gene therapies.”   Tapping into its deep expert...